ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,738.17
      -0.13%
      US Tech 100
      19,444.80
      -0.68%
      Dow Jones
      42,313.00
      0.33%
      Brent Oil
      71.965
      1.43%
      Bitcoin
      65,793.26
      0.94%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Akari Therapeutics PLC (AKTX)

      7. Akari Therapeutics PLC (AKTX) News

      AKTX

      Akari Therapeutics (AKTX)

      Akari Therapeutics PLC
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:AKTX
      DateTimeSourceHeadlineSymbolCompany
      09/18/20244:40PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKTXAkari Therapeutics PLC
      09/18/20244:36PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AKTXAkari Therapeutics PLC
      09/18/20244:34PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AKTXAkari Therapeutics PLC
      09/16/20244:05PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:AKTXAkari Therapeutics PLC
      09/16/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:AKTXAkari Therapeutics PLC
      09/13/20245:30PMEdgar (US Regulatory)Form S-4 - Registration of securities, business combinationsNASDAQ:AKTXAkari Therapeutics PLC
      09/06/20245:23PMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:AKTXAkari Therapeutics PLC
      08/23/20244:30PMEdgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:AKTXAkari Therapeutics PLC
      08/19/20244:30PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AKTXAkari Therapeutics PLC
      08/19/20244:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AKTXAkari Therapeutics PLC
      08/15/20244:15PMEdgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:AKTXAkari Therapeutics PLC
      06/20/20247:30AMEdgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:AKTXAkari Therapeutics PLC
      06/18/20244:15PMEdgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:AKTXAkari Therapeutics PLC
      06/07/20246:00PMEdgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:AKTXAkari Therapeutics PLC
      06/05/20245:00PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AKTXAkari Therapeutics PLC
      06/04/20244:45PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKTXAkari Therapeutics PLC
      06/04/20244:45PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKTXAkari Therapeutics PLC
      06/04/20248:02AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AKTXAkari Therapeutics PLC
      06/03/20244:21PMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:AKTXAkari Therapeutics PLC
      05/16/20248:05AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AKTXAkari Therapeutics PLC
      05/15/20244:47PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AKTXAkari Therapeutics PLC
      05/07/20245:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AKTXAkari Therapeutics PLC
      03/15/202412:53PMPR Newswire (US)Kuehn Law Encourages VIVK, MINM, SDPI, and AKTX Investors to Contact Law FirmNASDAQ:AKTXAkari Therapeutics PLC
      03/11/20245:25PMEdgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:AKTXAkari Therapeutics PLC
      03/11/20245:24PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AKTXAkari Therapeutics PLC
      03/05/20244:57PMEdgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:AKTXAkari Therapeutics PLC
      03/05/20248:34AMEdgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:AKTXAkari Therapeutics PLC
      03/05/20248:28AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AKTXAkari Therapeutics PLC
      01/09/20245:25PMEdgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:AKTXAkari Therapeutics PLC
      01/04/202412:34PMEdgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:AKTXAkari Therapeutics PLC
       Showing the most relevant articles for your search:NASDAQ:AKTX